Mechanisms and Research Progress of the Wnt/β-catenin Signalling Pathway in Hepatocellular Carcinoma
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v7i2.5324
Abstract
Hepatocellular carcinoma (HCC) is one of the most common primary liver cancers worldwide, and its development is a complex, multigenic, and multistep process. The Wnt/β-catenin signalling pathway, as a key regulator of cell proliferation, differentiation, apoptosis and migration, is frequently abnormally activated in HCC and represents a core molecular event promoting tumour initiation, progression, metastasis and treatment resistance.This article provides a systematic review of the core regulatory mechanisms of the Wnt/β-catenin signalling pathway, its role in the development of HCC, its interactions with the tumour microenvironment (TME) and other signalling pathways, as well as therapeutic strategies and research progress targeting this pathway. The aim is to provide a theoretical basis and new directions for the precision diagnosis and treatment of HCC.
Keywords
Wnt/β-catenin signalling pathway; hepatocellular carcinoma; mechanism of action; tumour microenvironment; targeted therapy; research progress
Full Text
PDF - Viewed/Downloaded: 3 TimesReferences
[1] Siegel R L, Miller K D, Fuchs H E, et al. Cancer statistics, 2024 [J]. CA: A Cancer Journal for Clinicians, 2024, 74 (1): 11-38.
[2] Villanueva A. Hepatocellular carcinoma: molecular pathways and targeted therapies [J]. Journal of Hepatology, 2019, 70 (4): 718-733.
[3] Nusse R, Clevers H. Wnt/β-catenin signalling, disease, and emerging therapeutic modalities [J]. Cell, 2017, 169 (7): 985–999.
[4] Malgorzata B, Anna M, Krzysztof P. Wnt/β-catenin signalling in hepatocellular carcinoma: role, mechanisms and therapeutic strategies [J]. Journal of Cellular Physiology, 2021, 236 (11): 7602-7618.
[5] Zhan T, Rindtorff N, Betz E, et al. Wnt signalling in cancer [J]. Oncogene, 2017, 36 (11): 1461-1473.
[6] Wang Hao, Li Peng, Wang Fusheng. Recent advances in the Wnt/β-catenin signalling pathway and hepatocellular carcinoma [J]. Chinese Journal of Hepatology, 2020, 28 (5): 438-442.
[7] Liu Chang, Zhang Yi. The role of non-coding RNA in regulating the Wnt/β-catenin pathway in hepatocellular carcinoma [J]. Research on Cancer Prevention and Treatment, 2022, 49 (3): 278-283.
[8] Yates L, Garraway I P. Targeting the Wnt pathway in cancer: progress and challenges [J]. Current Opinion in Pharmacology, 2018, 43: 106–113.
[9] Chen J, Li Y, Zhang H, et al. The tankyrase inhibitor XAV939 suppresses hepatocellular carcinoma growth by stabilising AXIN and inhibiting β-catenin signalling [J]. Cancer Letters, 2019, 458: 125–136.
[10] Kim T S, Jeon Y K, Kim S H, et al. PRI-724, a β-catenin/TCF inhibitor, enhances the antitumour efficacy of sorafenib in hepatocellular carcinoma [J]. British Journal of Cancer, 2021, 124 (5): 823–832.
[2] Villanueva A. Hepatocellular carcinoma: molecular pathways and targeted therapies [J]. Journal of Hepatology, 2019, 70 (4): 718-733.
[3] Nusse R, Clevers H. Wnt/β-catenin signalling, disease, and emerging therapeutic modalities [J]. Cell, 2017, 169 (7): 985–999.
[4] Malgorzata B, Anna M, Krzysztof P. Wnt/β-catenin signalling in hepatocellular carcinoma: role, mechanisms and therapeutic strategies [J]. Journal of Cellular Physiology, 2021, 236 (11): 7602-7618.
[5] Zhan T, Rindtorff N, Betz E, et al. Wnt signalling in cancer [J]. Oncogene, 2017, 36 (11): 1461-1473.
[6] Wang Hao, Li Peng, Wang Fusheng. Recent advances in the Wnt/β-catenin signalling pathway and hepatocellular carcinoma [J]. Chinese Journal of Hepatology, 2020, 28 (5): 438-442.
[7] Liu Chang, Zhang Yi. The role of non-coding RNA in regulating the Wnt/β-catenin pathway in hepatocellular carcinoma [J]. Research on Cancer Prevention and Treatment, 2022, 49 (3): 278-283.
[8] Yates L, Garraway I P. Targeting the Wnt pathway in cancer: progress and challenges [J]. Current Opinion in Pharmacology, 2018, 43: 106–113.
[9] Chen J, Li Y, Zhang H, et al. The tankyrase inhibitor XAV939 suppresses hepatocellular carcinoma growth by stabilising AXIN and inhibiting β-catenin signalling [J]. Cancer Letters, 2019, 458: 125–136.
[10] Kim T S, Jeon Y K, Kim S H, et al. PRI-724, a β-catenin/TCF inhibitor, enhances the antitumour efficacy of sorafenib in hepatocellular carcinoma [J]. British Journal of Cancer, 2021, 124 (5): 823–832.
Copyright © 2026 Jingyu Zhang, Jianmei Hao
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License